BSX Stock Set to Gain From the New Agreement to Acquire SoniVie Ltd.

Company Overview - Boston Scientific, Inc. (BSX) has signed a definitive agreement to acquire SoniVie Ltd., a privately held medical device company, for nearly $360 million upfront, with an additional$180 million contingent on regulatory milestones [1] - The transaction is expected to close in the first half of 2025, subject to customary closing conditions [1] Stock Performance - Following the acquisition announcement, BSX shares rose 1% to finish at $104.87 [2] - Over the past year, Boston Scientific shares have increased by 55.5$153.17 billion [3] - The Zacks Consensus Estimate for the company's 2025 earnings per share (EPS) is $2.85, indicating a 13.6$340.4 million in 2023 and is expected to grow at a compound annual growth rate of 40.2% through 2030 [7] Financial Impact of Acquisition - The transaction is expected to be slightly dilutive to Boston Scientific's adjusted EPS in 2025, but this will be offset by internal cost efficiencies [6] - On a GAAP basis, higher dilution is anticipated due to amortization expenses and acquisition-related charges, except for a one-time gain from the previously held equity interest in SoniVie [6] Future Prospects - The acquisition provides an opportunity for future innovation in the field of hypertension treatment, supported by strong clinical evidence and ongoing research [2] - Boston Scientific's strategy includes expanding its cardiovascular portfolio, as evidenced by a recent acquisition agreement with Bolt Medical, Inc. [9]